The following is a summary of the YS Biopharma Co., Ltd. (YS) Q3 2024 Earnings Call Transcript:
Financial Performance:
YS Biopharma reported a total revenue of RMB 438.1 million for the first nine months of fiscal year 2024, a year-over-year decrease by 24.6% due to supply chain disruptions.
Net loss of RMB 260 million was recorded for the same period.
The company projects double-digit growth in product sales for the end of fiscal year 2024 and throughout 2025.
Business Progress:
YS Biopharma successfully addressed inventory issues and balanced their strategy to meet market demands.
The company continues to strengthen relationships with CDC customers in China, constituting more than 6% of their network.
Priority placed on pre-clinical and clinical pipeline across all subsidiaries in the US, China, and Singapore.
Successful results from the Phase III trial of their PIKA rabies vaccine show potential for faster production and improved regimen.
The company plans to conduct a Phase 1 study for their Hepatitis B vaccine.
Tips: This article is generated by AI. The accuracy of the content can not be fully guaranteed. For more comprehensive details, please refer to the IR website. The article is only for investors' reference without any guidance or recommendation suggestions.